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ABSTRACT  Kawasaki disease (KD) is one of the most common vasculitis in childhood, 
but its etiology is still unknown. We hypothesized that Sulfamethoxazole / Trimethoprim (S/
T) would inhibit overproduction of cytokine due to heat shock protein produced by intestinal 
bacteria in patients with KD and improve the clinical course of KD indirectly. We have 
conducted a prospective study to assess the usefulness of S/T for KD. For patients with KD 
(S/T group, N=23), we use S/T in addition to the standard treatment in the guidelines such 
as intravenous immunoglobulin (IVIG) and moderate dose aspirin. The control group (non S/
T group, N=32) is patients with KD treated with the standard treatment in the guidelines. The 
baseline characteristics did not demonstrate notable differences between the two groups. 
We compare duration of fever, rate of initial IVIG failure, the day of illness membranous 
desquamation appeared, and the occurrence of coronary artery lesion (CAL) between two 
groups. Membranous desquamation appeared rather earlier in S/T group than in non S/T group 
(11.4±3.0 day of illness vs 12.9±3.5 day of illness, P=0.078), but there was no statistically 
significant difference. Duration of fever (39±59 hours vs 42±57 hours, P=0.41), rate of initial 
IVIG failure (26% vs 31%, P=0.30), and number of CAL (8.6% vs 9.3%, P=0.87) were found no 
significant difference between two groups. These data indicated that the use of S/T in acute 
phase of KD didn’t improve any clinical course of KD.
 doi：10.11482/KMJ-E40（2）65　(Accepted on June 12, 2014)
Key words： Kawasaki disease, Sulfamethoxazole / Trimethoprim, Heat shock protein, 
intravenous immunoglobulin therapy
Corresponding author
Atsushi Kato
Department of Pediatrics, Kawasaki Medical School, 
577 Matsushima, Kurashiki, 701-0192, Japan
Phone : 81 86 462 1111
Fax : 81 86 462 7897
E-mail: katoatsu@med.kawasaki-m.ac.jp
INTRODUCTION 
   Kawasaki disease (KD) is one of the most 
common vasculitis in childhood1,2). Its etiology and 
pathophysiology have remained unknown over 
45 years from the first report in 1969. A number 
of epidemiological and clinical observations 
suggest that KD is caused by an infectious agent, 
with suggestions ranging from Staphylococci, 
Streptococci, Yersinia, Mycoplasma or Chlamydia, 
to viruses such as adenovirus, parvovirus or 
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Epstein-Barr virus3-6). But so far, all theories are still 
controversial, because no single causative pathogen 
has been consistently demonstrated from patient 
with KD3-6). 
   In 2008, one group showed that serum heat shock 
protein (HSP) level is significantly higher in patients 
with KD than healthy children, because HSP is 
overproduced by intestinal bacteria in patients with 
KD7). And this report suggested that HSP act with 
superantigens to induce cytokine storm, is the cause 
and/or a factor of worsening KD.
   We hypothesized that oral antibiotics inhibit 
the production of HSP, and prevent to deteriorate 
KD. Although all bacteria to produce HSP and 
superantigen are sensitive to Sulfamethoxazole / 
Trimethoprim (S/T)7), little has been reported on the 
effectiveness of S/T to KD8). This is the first report 
evaluated the effect of oral S/T for KD.
METHOD
   From January 2010 to December 2012, children 
diagnosed with KD or suspected incomplete KD in 
Kawasaki Medical School Hospital were eligible for 
the enrolment of this study. After the consent of our 
study, S/T was orally administered 2 times per day at 
a dose of 0.05 g/kg/time for 7 consecutive days9,10). 
After the diagnosis of KD, we started intravenous 
immunoglobulin (IVIG) therapy at a dose of 2 g/kg 
and moderate dose of aspirin that conforms to the 
Clinical Guideline for Medical Treatment of Acute 
Stage Kawasaki Disease published by Japanese 
Society of Pediatric Cardiology and Cardiac 
Surgery (JSPCCS)11). After afebrile for 48 hours, the 
dose of aspirin was reduced to 3 to 5 mg/kg once 
daily, and continued to 90 days after onset. If they 
were unresponsive to first IVIG therapy, we added 
the treatment for initial IVIG poor responder in 
accordance with the guidelines11).
   Patient we didn’t consent from and patients 
whose AST and/or ALT was more than 300 IU/L 
on admission were excluded, because S/T might 
exacerbate hepatopathy9,10).
   Patients who presented with coronary artery legion 
(CAL) before the initial treatment began were also 
excluded from the study.
   The control group (non S/T group) was patients 
with KD treated in accordance with the guidelines 
in Kawasaki Medical School Hospital between 
January, 2006 and December, 2012. We compared 
these two groups for using or non-using S/T in 
patients with KD. We compared duration of fever, 
rate of initial IVIG failure, the day of illness 
membranous desquamation appeared, and the 
occurrence of CAL of these two groups.
   The trial was also adapted after agreement from 
the funders and ethics committee at Kawasaki 
Medical School.
Diagnosis
   Our criteria for a diagnosis of KD included fever 
(temperature ≧38°C) accompanied by the presence 
of at least 4 of the following 5 findings: bilateral 
conjunctival injection, changes in the lips and the 
oral cavity, nonpurulent cervical lymphadenopathy,
polymorphous exanthema, and changes in the 
extremities.
   These diagnostic criteria are based on the 
Diagnostic Guidelines for Kawasaki Disease (5th 
revision)12). The first day of illness was defined 
as the first day fever was present. Patients were 
excluded if the clinical or laboratory evidence 
suggested atypical KD13) or any other disease known 
to mimic KD, such as adenovirus infection, Epstein-
Barr virus infection, scarlet fever, or bacterial 
cervical lymphadenitis. 
Requirements for Additional Treatment after initial 
IVIG
   Additional treatment was provided when patients 
had persistent fever lasting 24 hours after the 
completion of the initial IVIG treatment or in the 
presence of recrudescent fever associated with 
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KD symptoms after an afebrile period11). We use 
ulinastatin in addition to 2nd IVIG therapy as 
additional treatment14).
Assessment of Coronary Artery Lesions (CAL)
   A pediatric cardiologist had recurrently assessed 
the  coronary ar ter ies  us ing 2-dimensional 
echography, and we reviewed their records at least 
1 month after the onset of KD. In accordance with 
the Japanese Ministry of Health criteria, CAL was 
diagnosed when any of the examinations resulted in 
the following findings14): an internal lumen diameter 
＞3.0 mm in a child ＜5 years of age or ＞4.0 mm 
in a child ≧5 years of age, an internal segment 
diameter at least 1.5 times larger than that of an 
adjacent segment, or an irregular lumen.
Assessment of Adverse Events
   Adverse events associated with S/T, such as the 
elevation of transaminase, neutropenia, rash, and 
hyperkalemia were reported9,10). In the present study, 
neutropenia was diagnosed when the neutrophil 
count decreased to 1500 cells/mm³. Every 2-4 
days, we performe blood tests to find occurrence 
of adverse events after admission of S/T until their 
discharge.
Analyses
   Statistical analysis was performed by using ystat 
2008. Means, medians, and ranges were calculated 
for descriptive data. Analyses of clinical features 
were performed by using the Fisher exact or x² 
tests for categorical variables and Wilcoxon test for 
numerical variables. Univariate analyses of features 
predicting an adverse outcome were performed 
by using logistic regression. A P value ＜0.05 was 
accepted as statistically significant.
RESULT
S/T group
   From January 2010 to December 2012, there 
are 50 hospitalizations for patients diagnosed with 
KD or suspected KD in Kawasaki medical school 
hospital. 1 mimic KD and 7 atypical KD were 
excluded from this study, because they didn’t meet 
our KD criteria. 42 KD patients were enrolled to 
this study. 1 case was excluded because of CAL 
before the initial treatment began, and 4 cases were 
excluded because of elevated transaminase, and 3 
cases were excluded because they didn’t need IVIG 
Fig. 1.　Flowchart of the patients enrolled in this study.
Figure1: Flowchart of the patients enrolled in this study.
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therapy. We tried to get consents from 34 cases, 
and 7 patients we couldn’t get consent from their 
family were excluded from S/T group. (7 patients 
we couldn’t get consent were enrolled as non S/T 
group.) We tried to administer S/T for 27 patients, 
but 4 patients couldn’t take orally S/T because of 
bitter taste of KD. Finally, we register 23 patients 
were eligible to the S/T group in our study (Fig. 1).
Non S/T group
   From January 2006 to December 2009, there 
are 38 hospitalizations for patients diagnosed with 
KD or suspected KD in Kawasaki medical school 
hospital. 1 mimic KD and 5 atypical KD were 
excluded from this study, because they didn’t meet 
our KD criteria. Further, 7 patients we couldn’t get 
consent to participate in S/T group were enrolled as 
candidates of non S/T group.
   4 cases were excluded because of elevated 
transaminase, and 1 case was excluded because 
the patient didn’t take IVIG therapy. Finally, we 
enrolled 32 patients as non S/T group. There was 
no patient CAL before the initial treatment began in 
non S/T group (Fig. 1).
Characteristics and Laboratory Findings of the 
Patients
   Twenty three patients in the S/T group and 32 
patients in the control group (non S/T group) were 
included in the present study. Table 1 describes the 
baseline characteristics and laboratory findings for 
the S/T group and the control group. No significant 
differences were found between the S/T group and 
the control group.
Duration of fever
   Average time to become antipyretic from starting 
first IVIG is 39±59 hours in S/T group, and 42±
57 hours in non S/T group. (P=0.41) These are no 
significant difference (Table 2).
Requirements for Additional Rescue Treatment
   Six cases (26%) in S/T group and 10 cases (31%) 
in non S/T group needed to use additional treatment 
because of poor response to initial IVIG. (P=0.30) 
The percentages of initial IVIG failure are no 
significant difference between two groups (Table 2).
The day of illness membranous desquamation 
appeared
   Membranous desquamation, an indication of 
convalescence, appeared rather earlier in S/T group 
than in non S/T group (11.4±3.0 day of illness vs 
12.9±3.5 day of illness, P=0.078), but these were 
no statistically significant difference between two 
groups (Table 2).
Comparison of the Coronary Artery Outcomes
   We found two cases (8.6%) of coronary artery 
aneurysms in ST group, and three cases (9.3%) in 
Table 1. Characteristics of study patients
S/T group Non S/T gruop P value
n 23 32
Age（months, mean±SD） 25.1±19.3 30.4±22.5 0.18
WBC（/μL , mean±SD） 13,300±3,550 12,300±4,170 0.17
CRP（mg/dL, mean±SD） 8.0±3.6 6.8±5.5 0.15
AST（IU/L, mean±SD） 69±10 46±20 0.10
ALT（IU/L, mean±SD） 72±87 49±53 0.10
Alb（mg/dL , mean±SD） 3.6±0.4 3.8±0.4 0.06
T-bil（mg/dL, mean±SD） 0.7±0.7 1.0±1.0 0.15
Gunma score（mean±SD） 3±1.7 2.9±2.1 0.39
The day we used ﬁrst IVIG
（Days ± SD） 5.0±1.3 4.6±1.2 0.17
69Kato A, et al. : S / T confer no change on the clinical course of KD.
non S/T group. (P=0.87) These all 5 cases of CAL 
were evanescent small aneurythms. And it was 
confirmed that all CAL has disappeared in follow 
up echocardiogram three months after from onset of 
KD (Table 2).
Assessment of Adverse Events
   In S/T group, two cases of evanescent neutropenia 
that were believed to have been caused by S/T were 
observed during their admissions. These two cases 
of neutropenia were improved with no treatment 
a few days after from onset of their neutropenia. 
And no infectious disease due to neutropenia was 
observed.
DISCUSSION
   Although we hypothesized that early admission of 
oral S/T improve the prognosis of KD, our study has 
disclosed that S/T don’t result in any effects on the 
clinical course of KD in acute phase. These results 
are consistent with the common knowledge, it is 
well known, that antimicrobial agents are ineffective 
for KD. 
   Our study has several limitations to evaluate 
the effectiveness of S/T for KD. First, we didn’t 
measure serum HSP level and serum cytokine level 
at any time. It was reported all bacteria to produce 
HSP are sensitive to S/T7). We assume that S/T 
inhibit to produce HSP and cytokine in patient with 
KD. In our study, membranous desquamation, a 
feature in recovery period for KD12), has appeared 
more early in S/T group than in control group, but 
there were no significant differences. This result 
suggests that S/T bring early recovery phase because 
of suppressing the production of HSP in acute phase 
of KD. But we couldn’t prove it because of racking 
the data of serum HSP level.
   Secondly, we might have excluded severe KD 
from our study. In severe KD, many values such as 
serum albumin, transaminase and bilirubin tend to 
be abnormal values15,16). Because we couldn’t use S/
T for the cases with high transaminase (≧300 IU/
L) for fear of exacerbation of liver failure, we might 
exclude severe KD from this study. We guess S/T is 
effective to suppress cytokine storm for severe KD 
more than not severe KD, but we can’t use S/T for 
severe KD for fear of side effects of S/T15,16). We 
believe it is a reason we can’t show any significant 
difference between two groups in our study.
   Thirdly, there are few cases which needed 
additional IVIG therapy, because our study 
population is small. Nagata et al. reported S/
T is effective to KD which is unresponsive to 
IVIG. In this report, Nagata et al. administered S/
Table 2. Clinical outcome of the two groups
S/T group Non S/T group P value
n 23 32
The refractory rate of
Initial IVIG therapy
n（%）
6（26%） 10（31%） 0.30
The antipyretic day
 (Days ± SD） 7.5±2.2 7.1±2.8 0.30
Duration from initial
IVIG to antipyretic
(Hours ± SD）
39±59 42±57 0.41
The day of membranous
desquamation
(Days ± SD）
11.4±3.0 12.9±3.5 0.078
CAL
n（%） 2（8.6%） 3（9.3%） 0.87
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T for 7 cases of KD that were unresponsive to 
second IVIG therapy and studied the antipyretic 
potency of the treatment8). In 6 out of the 7 cases, 
they demonstrated that antipyretic potency was 
observed without side effects within 2 days of 
the initial administration. In spite of most severe 
cases, the coronary lesions didn’t deteriorate with 
the exception of the 1 case that had formed giant 
aneurysms. And no side effects believed to have 
been caused by S/T were observed during the course 
of treatment or follow-up in this report. We couldn’t 
compare the effectiveness of S/T for IVIG resistant 
KD because our study hasn’t enough number of 
patients with KD.
   Nagata et al. suggests S/T is safe and effective for 
patient with severe KD in acute phase8). In contrast, 
we provide evidence that S/T is not effective for 
patient with mild KD. And we can’t compare the 
effectiveness of S/T for severe KD. Therefore 
the usefulness of S/T for patient with KD is still 
controversial. We try to increase the number of 
cases and plan a new randomized control trial to 
assess the usefulness of S/T for patient with severe 
KD in acute phase. Further evidence will be needed.
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